drugset / Trial / NCT03091257
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
Phase 1
Active not recruiting
30 enrolled
Massachusetts General Hospital
Barbara Ann Karmanos Cancer Institute · collabMultiple Myeloma Research Consortium · collabNovartis · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research study is studying a targeted therapy as a possible treatment for multiple myeloma. The names of the study drugs involved in this study are: * Trametinib * Dabrafenib
Timeline
- Start
- 2017-06-21
- Primary completion
- 2026-07-15
- Completion
- 2026-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabrafenib | Small molecule | — | Oral |
| Subject | Trametinib | Small molecule | — | Oral |